Last reviewed · How we verify
NCT03521362
MyT1DHero: an mHealth Intervention for Type 1 Diabetes
NA trial testing MyT1DHero in Type1diabetes in 33 participants. Completed in 1 December 2021.
1 December 2021
Quick facts
| Lead sponsor | Michigan State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 33 |
| Start date | 1 January 2019 |
| Primary completion | 1 December 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MyT1DHero
- Other T1D Mobile App
Conditions studied
- Type1diabetes — all drugs for Type1diabetes →
Sponsor
Michigan State University
Who can join
Adults 10 to 15, any sex, with Type1diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of the proposed research is to improve HbA1c, adherence to treatment plans, and family communication surrounding adolescents' self-management of T1D. The investigators will test the efficacy of the MyT1DHero app against an attention control group. This will allow investigators to better understand the health and psychosocial improvements being made through the app.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03521362
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MyT1DHero
Trials testing the same drug.
- NCT03436628 — Using an mHealth App to Transition Care of Type-1 Diabetes From Parents to Teens · NA · completed
Other recruiting trials for Type1diabetes
Currently open trials in the same condition.
- NCT07139808 — Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System · NA · recruiting
- NCT07092761 — Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System · NA · recruiting
- NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
- NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
- NCT05668507 — REACHOUT Mental Health Support Mobile App · NA · active not recruiting
Other Michigan State University trials
Trials by the same sponsor.
- NCT06325150 — The Impact of Light Exposure on Cognitive Function in Classrooms · Phase 1 · not yet recruiting
- NCT07213284 — Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial · NA · not yet recruiting
- NCT07164391 — Empowering Vietnamese Americans · NA · not yet recruiting
- NCT04521972 — Impact of Room Light on Uterine Contractions and Labor Progression in Pregnancy · NA · recruiting
- NCT05358964 — Family Health Histories: Creating a Culturally Tailored Tool to Reduce Health Disparities in the Black Community · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03521362 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Michigan State University
- Last refreshed: 25 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03521362.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing